GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

Affected assets and topics

Expected market reaction

Evidence trail

Prediction lifecycle

• Rule-Based Analysis not AI RACE Neutral 50% 6h
  Generated → 6h → Excluded

  Expired: not evaluated within 7 days of its 6h timeframe elapsing

Logged at publication, scored automatically once the window closes — never edited.

Original source

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

Read the full article on CNBC

Original article published by CNBC on June 9, 2026. Analysis and insights provided by AnalystMarkets AI.

More of the RACE narrative

• 04:00 The race to stop AI from designing bioweapons Financial Times
• 07:37 UK Takeovers Race Past $100 Billion After Summer Deals Surge Bloomberg
• 07:11 How Aston Martin’s latest financing sparked a bondholder revolt Financial Times
• 04:18 South Korea sets record US$600 billion budget, backed by chip windfall South China Morning Post